Accendra Health (ACH) Reports 2025 Revenue of $2.8B and Shift Toward Core Home-Based Care

Accendra Health Inc. (NYSE:ACH) is one of the most undervalued penny stocks to buy right now. On February 19, Accendra Health reported full-year 2025 revenue of nearly $2.8 billion, which was a 3% year-over-year increase. Despite this growth, Q4 adjusted EBITDA fell to $90 million from $102.5 million in the prior year, bringing the annual total to $375 million. This progress was supported by the sale of the company’s former products and healthcare services business, allowing the firm to focus on its core home-based care brands, Byram and Apria.

Accendra Health Inc. (NYSE:ACH) faces significant headwinds heading into 2026, primarily due to the loss of a large commercial payer, which is expected to reduce revenue by $300 million. Consequently, 2026 revenue guidance is set at $2.55 to $2.65 billion, with adjusted EBITDA projected at $335 to $355 million. Management also noted challenges from inflationary product costs and stranded costs related to the recent divestiture.

These factors are expected to result in a weaker H1 2026, with only 40% of the year’s adjusted EBITDA anticipated during that period as cost-reduction initiatives ramp up. Strategic priorities for the coming year center on debt reduction and operational efficiency through technology, such as the MyApria app. The CFO projected free cash flow of at least $100 million for 2026.

Accendra Health Inc. (NYSE:ACH), together with its subsidiaries, operates as a healthcare solutions company in the US. It offers a range of products & services for in-home care & delivery for diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment.

While we acknowledge the potential of ACH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Profitable Undervalued Stocks to Buy and 11 Best Mining Stocks to Buy According to Wall Street.

Disclosure: None.